Pediatric Providers and Hiv Pre-exposure Prophylaxis

Background Pre-exposure prophylaxis (PrEP) is the newest biomedical HIV prevention option. The daily tenofovir/emtricitabine (Truvada) combination pill reduces the risk of HIV infection by up to 92% compared to placebo (1). While PrEP use is increasingly common in adult LGBT populations, only a handful of studies have investigated introducing PrEP to adolescent providers and patients. Adolescents are the fastest growing age group of HIV positive patients and LGBT youth are at even higher risk. Nationally, 19% of new HIV infections occur in LGBT youth. HIV infections in LGBT youth …